ALB and neoplasm: Kim et al. [147] reported that CUR-loaded human serum albumin (HSA) nanoparticles (CUR–HSA–NPs) showed increased in vivo antitumor effect in comparison with the unformulated CUR, with no toxicity in a tumor xenograft animal model.